Why the study?
Does the magnitude of QTc prolongation predict a stronger association with Torsades de Pointes for non-antiarrhythmic drugs?
Observational (n=30)
Does the magnitude of QTc prolongation predict a stronger association with Torsades de Pointes for non-antiarrhythmic drugs?
Specific QTc prolongation cut-off values (e.g., >12 ms in monotherapy) can help distinguish drugs with a strong potential for Torsades de Pointes from those with borderline risk.
Answers are grounded in this paper and cite their sources.
Supports QTc magnitude for torsades risk stratification; leaves open whether thresholds should guide prescribing without prospective validation.
PURPOSE: Drug induced Torsades de Pointes (TdP) is a major concern for new drugs seeking regulatory approval. Prolongation of QT intervals greater than 60 millisecond or to longer than 500 millisecond in an individual patient has been considered to be associated with a higher risk. The purpose of this study is to identify values inferred from a population that predict a stronger potential for TdP. METHODS: Prolongation data of 30 non-antiarrhythmic QT prolonging drugs were analysed. Depending on how strong the drugs were associated with TdP, they were categorized as strong or borderline torsadogens. The differences in mean QTc increases between the two groups were compared and cut-off values that distinguished strong from borderline drugs were searched for. RESULTS: The average QTc increase of 19.3 millisecond of strong torsadogens was significantly greater than the 8.0 millisecond of borderline torsadogens. Prolongation greater than 12 millisecond in the context of monotherapy or 25 millisecond in the presence of metabolic inhibition and an upper bound of 95% confidence interval (CI) for the mean QTc increase greater than 14 millisecond in monotherapy or 30.1 millisecond in combination therapy with metabolic inhibitors favoured a stronger association with TdP. CONCLUSIONS: Drugs strongly associated with TdP have greater QTc increases than those with less concern. Several cut-off values have been noted to distinguish between them. These values may be helpful for evaluation of TdP risk for future QT prolonging drugs.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2009) conducted an observational in Drug induced Torsades de Pointes (n=30). Strong torsadogenic drugs vs. Borderline torsadogenic drugs was evaluated on Average QTc increase.
Synapse has enriched 10 related papers. Consider them for comparative context: